ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1482

Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment

Erik Cimé-Aké1, Guadalupe Lima1, Emilio Godinez-Lazarini1, Sandra Juárez1, Hilda Marín-López1, Amairani Gómez-Rodríguez1, Daniela Flores-Hernández1, Ileana Flores-Hernández1, Diego F. Hernández-Ramírez1, Luis Llorente1 and Hilda Fragoso-Loyo2, 1Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico

Meeting: ACR Convergence 2025

Keywords: Cognitive dysfunction, Systemic lupus erythematosus (SLE), T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) may be associated with different T cell subpopulations distribution and chronic pro-inflammatory state in which immunosenescence could be involved. This study investigates the distribution of T cell subpopulations and immunosenescent markers in SLE patients with CI.

Methods: We included women aged 18-50 years, classified with SLE according to the EULAR/ACR 2019 criteria. Women with other autoimmune diseases except antiphospholipid syndrome or Sjögren’s syndrome, administration of any biologic drug < 6 months prior to study entry, clinical SLEDAI-2K >0, SDI ≥1, current prednisone >7.5 mg/day, education level ≤6 years, pregnancy or premature ovarian failure, active infection, malignant disease, history of other neuropsychiatric manifestations, other chronic comorbidities or major depressive disorder were excluded. We also include healthy women (HC) paired for age ±5 years. We applied a neurocognitive battery, assessing eight cognitive domains: concentration, verbal memory, visuospatial memory, language, processing speed, motor speed, problem solving and executive function. CI was defined when a subject had scores ≥2 standard deviation below the mean of the normative data in at least one cognitive domain. According to the neurocognitive assessment patients were classified as: SLE with CI, SLE without CI and HC. The lymphocyte subpopulation profile for each patient was determined by flow cytometry. A CD4+/CD8+ ratio of < 1 (inverted ratio) was considered a marker of immunosenescence. The relative expression of the p16INK4a gene in CD3+ T lymphocytes was considered another marker of immunosenescence and was assessed through CD3+ cell purification from peripheral blood, RNA extraction, qPCR, and evaluation of relative expression (ddCT) normalized to the housekeeping gene GAPDH. Demographic and clinical data were also recorded.

Results: Fifteen patients in each group were included. The median age of patients studied was similar. SLE patients with CI had lower educational level than the SLE without CI and HC, and longer disease duration compared to SLE patients without CI. Disease activity and accrual damage was similar between the SLE groups (Table 1). In SLE patients with CI, the most frequently impaired cognitive domain was motor speed (73.3%), followed by visuospatial memory (33.3%), processing speed (13.3%), verbal memory (6.6%), language (6.6%), and problem solving (6.6%) (Figure 1). SLE patients with CI had significant lower levels of naive CD4+T cells and higher levels of CD8+ T cells compared to the other groups. The proportion of inverted CD4+/CD8+ ratio and relative expression of p16INK4a were greater in SLE with CI compared to SLE without CI and HC groups (53.3% vs. 20.0% vs. 0%, p=0.003 and 1.6 [1.0-2.3] ddCT vs. 0.8 [0.4-2.2] ddCT vs. 0.6 [0.5-1.0] ddCT, p=0.005, respectively) (Table 1, Figure 2).

Conclusion: In SLE with CI there were lower levels of naïve CD4+ T-cells, higher levels of CD8+ T cells and greater presence of immunosenescence markers compared to SLE without CI and HC. The study suggests the possibility that immunosenescence may play a role in CI in SLE.

Supporting image 1Data are expressed as proportions (percentages) or medians (interquartile ranges). Statistical analysis: Chi-square or Fisher’s exact tests were used for nominal variables, the Kruskal-Wallis test was used for numerical variables. CM: central memory, EM: effector memory, TEMRA: effector memory T cells re-expressing CD45RA. *Statistically significant.

Supporting image 2Figure 1. Impaired cognitive domains in SLE patients with CI.

Data are expressed as percentages.

Supporting image 3Figure 2. Statistical significant differences in subpopulations and senescent markers in T cells of studied patients.

HC: healthy control, SLE: systemic lupus erythematosus, CI: cognitive impairment.


Disclosures: E. Cimé-Aké: None; G. Lima: None; E. Godinez-Lazarini: None; S. Juárez: None; H. Marín-López: None; A. Gómez-Rodríguez: None; D. Flores-Hernández: None; I. Flores-Hernández: None; D. Hernández-Ramírez: None; L. Llorente: None; H. Fragoso-Loyo: None.

To cite this abstract in AMA style:

Cimé-Aké E, Lima G, Godinez-Lazarini E, Juárez S, Marín-López H, Gómez-Rodríguez A, Flores-Hernández D, Flores-Hernández I, Hernández-Ramírez D, Llorente L, Fragoso-Loyo H. Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-t-cell-subpopulations-cd4-cd8-ratio-and-p16ink4a-in-patients-with-systemic-lupus-erythematosus-and-cognitive-impairment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-t-cell-subpopulations-cd4-cd8-ratio-and-p16ink4a-in-patients-with-systemic-lupus-erythematosus-and-cognitive-impairment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology